Salman, T. Et Al. 2016. Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.. Gastrointestinal Cancers Symposium , (San-Francisco, Costa Rica).

Salman, T., Bilici, A., Arslan, C., Varol, U., Yildiz, İ., Akyol, M., ... Yildiz, Y.(2016). Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer. . Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica

Salman, Tarik Et Al. "Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.," Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 2016

Salman, Tarik Et Al. "Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.." Gastrointestinal Cancers Symposium , San-Francisco, Costa Rica, 2016

Salman, T. Et Al. (2016) . "Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.." Gastrointestinal Cancers Symposium , San-Francisco, Costa Rica.

@conferencepaper{conferencepaper, author={Tarik Salman Et Al. }, title={Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.}, congress name={Gastrointestinal Cancers Symposium}, city={San-Francisco}, country={Costa Rica}, year={2016}}